ACHE and early-onset autosomal dominant Alzheimer disease: Tacrine was the first acetylcholinesterase inhibitor (AChEI) introduced in therapy for the treatment of Alzheimer's disease (AD) [1], which was used to increase the levels of acetylcholine, a neurotransmitter in the brain that was involved in learning and memory [2].